Journal of Digestive Cancer Research 2013; 1(1): 17-23
Published online March 1, 2013
© Korean Society of Gastrointestinal Cancer
Over the decades, the treatment of the esophageal cancer has been debated. Multimodal therapy is a important keystone in advanced esophageal cancer. Neoadjuvant chemoradiation therapy is now known to provide advantages for treating stage II and stage III esophageal squamous cell cancer and can also be considered for the esophageal adenocarcinoma. Definitive chemoradiation therapy results in long-term survival compared with surgery alone. This review aims to provide recent consensus recommendations based on the data and literatures.
Journal of Digestive Cancer Research 2013; 1(1): 17-23
Published online March 1, 2013
Copyright © Korean Society of Gastrointestinal Cancer Research.
전준한·정대영
가톨릭대학교 의과대학 내과학교실
Joon Han Jeon, Dae Young Cheung
Department of Internal Medicine, The Catholic University of Korea College of Medicine, Seoul, Korea
Over the decades, the treatment of the esophageal cancer has been debated. Multimodal therapy is a important keystone in advanced esophageal cancer. Neoadjuvant chemoradiation therapy is now known to provide advantages for treating stage II and stage III esophageal squamous cell cancer and can also be considered for the esophageal adenocarcinoma. Definitive chemoradiation therapy results in long-term survival compared with surgery alone. This review aims to provide recent consensus recommendations based on the data and literatures.
Keywords: cancer, Treatment